OBJECTIVES: This study sought to determine the rate of use of target doses of foundational guideline-directed medical therapy (GDMT) in a contemporary cohort of patients with heart failure with reduced ejection fraction (HFrEF) across systolic blood pressure (SBP) categories. BACKGROUND: Patients with HFrEF are infrequently titrated to recommended doses of GDMT. The relationship between SBP and achieving GDMT target doses is not well studied. METHODS: Patients enrolled in the CHAMP-HF (Change the Management of Patients With Heart Failure) registry without documented intolerance to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), and beta blockers (BBs) were assessed at enrollment. We estimated the proportion receiving target doses (% of target dose [95% confidence interval (CI)]) based on the most recent American College of Cardiology/American Heart Association/Heart Failure Society of America heart failure guidelines at baseline in all patients, and by SBP category (≥110 vs. <110 mm Hg). RESULTS: Of the 3,095 patients eligible for analysis, 2,421 (78.2%) had SBP ≥110 mm Hg. The proportion of patients receiving target doses were 18.7% (95% CI: 17.3% to 20.0%; BB), 10.8% (95% CI: 9.7% to 11.9%; ACEI/ARB), and 2.0% (95% CI: 1.5% to 2.5%; ARNI). Among those with SBP <110 mm Hg (n = 674), 17.5% (95% CI: 14.6% to 20.4%; BB), 6.2% (95% CI: 4.4% to 8.1%; ACEI/ARB), and 1.8% (95% CI: 0.8% to 2.8%; ARNI) were receiving target doses. Among those with SBP ≥110 mm Hg (n = 2,421), 19.0% (95% CI: 17.4% to 20.6%; BB), 12.1% (95% CI: 10.8% to 13.4%; ACEI/ARB), and 2.0% (95% CI: 1.5% to 2.6%; ARNI) were receiving target doses. CONCLUSIONS: In a large, contemporary registry of outpatients with chronic HFrEF eligible for treatment with BBs and ACEI/ARB/ARNI, <20% of patients were receiving target doses, even among those with SBP ≥110 mm Hg.
OBJECTIVES: This study sought to determine the rate of use of target doses of foundational guideline-directed medical therapy (GDMT) in a contemporary cohort of patients with heart failure with reduced ejection fraction (HFrEF) across systolic blood pressure (SBP) categories. BACKGROUND:Patients with HFrEF are infrequently titrated to recommended doses of GDMT. The relationship between SBP and achieving GDMT target doses is not well studied. METHODS:Patients enrolled in the CHAMP-HF (Change the Management of Patients With Heart Failure) registry without documented intolerance to angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), and beta blockers (BBs) were assessed at enrollment. We estimated the proportion receiving target doses (% of target dose [95% confidence interval (CI)]) based on the most recent American College of Cardiology/American Heart Association/Heart Failure Society of America heart failure guidelines at baseline in all patients, and by SBP category (≥110 vs. <110 mm Hg). RESULTS: Of the 3,095 patients eligible for analysis, 2,421 (78.2%) had SBP ≥110 mm Hg. The proportion of patients receiving target doses were 18.7% (95% CI: 17.3% to 20.0%; BB), 10.8% (95% CI: 9.7% to 11.9%; ACEI/ARB), and 2.0% (95% CI: 1.5% to 2.5%; ARNI). Among those with SBP <110 mm Hg (n = 674), 17.5% (95% CI: 14.6% to 20.4%; BB), 6.2% (95% CI: 4.4% to 8.1%; ACEI/ARB), and 1.8% (95% CI: 0.8% to 2.8%; ARNI) were receiving target doses. Among those with SBP ≥110 mm Hg (n = 2,421), 19.0% (95% CI: 17.4% to 20.6%; BB), 12.1% (95% CI: 10.8% to 13.4%; ACEI/ARB), and 2.0% (95% CI: 1.5% to 2.6%; ARNI) were receiving target doses. CONCLUSIONS: In a large, contemporary registry of outpatients with chronic HFrEF eligible for treatment with BBs and ACEI/ARB/ARNI, <20% of patients were receiving target doses, even among those with SBP ≥110 mm Hg.
Authors: L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes Journal: Ann Intern Med Date: 2001-11-06 Impact factor: 25.391
Authors: Mihai Gheorghiade; Muthiah Vaduganathan; Andrew Ambrosy; Michael Böhm; Umberto Campia; John G F Cleland; Francesco Fedele; Gregg C Fonarow; Aldo P Maggioni; Alexandre Mebazaa; Mandeep Mehra; Marco Metra; Savina Nodari; Peter S Pang; Piotr Ponikowski; Hani N Sabbah; Michel Komajda; Javed Butler Journal: Heart Fail Rev Date: 2013-03 Impact factor: 4.214
Authors: Adam D DeVore; Laine Thomas; Nancy M Albert; Javed Butler; Adrian F Hernandez; J Herbert Patterson; John A Spertus; Fredonia B Williams; Stuart J Turner; Wing W Chan; Carol I Duffy; Kevin McCague; Xiaojuan Mi; Gregg C Fonarow Journal: Am Heart J Date: 2017-04-29 Impact factor: 4.749
Authors: Manuel Montero-Perez-Barquero; Marcus Flather; Michael Roughton; Andrew Coats; Michael Böhm; Dirk J Van Veldhuisen; Daphne Babalis; Alain Cohen Solal; Luis Manzano Journal: Eur J Heart Fail Date: 2014-07-17 Impact factor: 15.534
Authors: Ankeet S Bhatt; Adam D DeVore; Tracy A DeWald; Karl Swedberg; Robert J Mentz Journal: J Am Coll Cardiol Date: 2017-05-23 Impact factor: 24.094
Authors: M R Bristow; E M Gilbert; W T Abraham; K F Adams; M B Fowler; R E Hershberger; S H Kubo; K A Narahara; H Ingersoll; S Krueger; S Young; N Shusterman Journal: Circulation Date: 1996-12-01 Impact factor: 29.690
Authors: Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Michele Robertson; Athanasios J Manolis; Luigi Tavazzi; Karl Swedberg Journal: Eur J Heart Fail Date: 2014-06-24 Impact factor: 15.534
Authors: Inder S Anand; Thomas S Rector; Michael Kuskowski; Sabu Thomas; N J Holwerda; Jay N Cohn Journal: Circ Heart Fail Date: 2008-05 Impact factor: 8.790
Authors: Milton Packer; John J V McMurray; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael Zile; Karl Andersen; Juan Luis Arango; J Malcolm Arnold; Jan Bělohlávek; Michael Böhm; Sergey Boytsov; Lesley J Burgess; Walter Cabrera; Carlos Calvo; Chen-Huan Chen; Andrej Dukat; Yan Carlos Duarte; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzàlez-Medina; Albert A Hagège; Jun Huang; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Ömer Kozan; Edmundo Bayram Llamas; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix J A Ramires; Jens Refsgaard; Arvo Rosenthal; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain B Squire; Randall C Starling; John R Teerlink; Johan Vanhaecke; Dragos Vinereanu; Raymond Ching-Chiew Wong Journal: Circulation Date: 2014-11-17 Impact factor: 29.690
Authors: Mohamad Khattab; Purvi Parwani; Mubasher Abbas; Huzair Ali; Pedro M Lozano; Udho Thadani; Tarun W Dasari Journal: J Family Med Prim Care Date: 2020-06-30
Authors: Matteo Serenelli; Michael Böhm; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Scott D Solomon; David L DeMets; Olof Bengtsson; Mikaela Sjöstrand; Anna Maria Langkilde; Inder S Anand; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Mirta Diez; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Subodh Verma; Kieran F Docherty; Pardeep S Jhund; John J V McMurray Journal: Eur Heart J Date: 2020-09-21 Impact factor: 29.983